vs
Clearwater Analytics Holdings, Inc.（CWAN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Clearwater Analytics Holdings, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.0倍（$217.5M vs $207.3M），Clearwater Analytics Holdings, Inc.净利率更高（-5.4% vs -62.0%，领先56.6%），Clearwater Analytics Holdings, Inc.同比增速更快（72.0% vs 25.9%），Clearwater Analytics Holdings, Inc.自由现金流更多（$52.3M vs $-100.8M），过去两年Clearwater Analytics Holdings, Inc.的营收复合增速更高（45.5% vs 38.0%）
Clearwater Analytics Holdings是美国SaaS金融科技企业，面向全球客户提供自动化投资会计、业绩测算、合规管理及风险报告服务。公司为公开上市企业，总部位于美国爱达荷州博伊西，在伦敦、爱丁堡、纽约、诺伊达多地设有分支机构。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CWAN vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $217.5M | $207.3M |
| 净利润 | $-11.8M | $-128.6M |
| 毛利率 | 67.2% | — |
| 营业利润率 | -3.1% | -54.7% |
| 净利率 | -5.4% | -62.0% |
| 营收同比 | 72.0% | 25.9% |
| 净利润同比 | -102.8% | 3.5% |
| 每股收益（稀释后） | $-0.04 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $217.5M | $207.3M | ||
| Q3 25 | $205.1M | $159.9M | ||
| Q2 25 | $181.9M | $166.5M | ||
| Q1 25 | $126.9M | $139.3M | ||
| Q4 24 | $126.5M | $164.6M | ||
| Q3 24 | $115.8M | $139.5M | ||
| Q2 24 | $106.8M | $147.0M | ||
| Q1 24 | $102.7M | $108.8M |
| Q4 25 | $-11.8M | $-128.6M | ||
| Q3 25 | $-10.3M | $-180.4M | ||
| Q2 25 | $-23.2M | $-115.0M | ||
| Q1 25 | $6.5M | $-151.1M | ||
| Q4 24 | $419.3M | $-133.2M | ||
| Q3 24 | $3.6M | $-133.5M | ||
| Q2 24 | $-430.0K | $-131.6M | ||
| Q1 24 | $1.9M | $-170.7M |
| Q4 25 | 67.2% | — | ||
| Q3 25 | 65.6% | — | ||
| Q2 25 | 65.1% | — | ||
| Q1 25 | 73.3% | — | ||
| Q4 24 | 73.5% | — | ||
| Q3 24 | 72.9% | — | ||
| Q2 24 | 72.0% | — | ||
| Q1 24 | 72.6% | — |
| Q4 25 | -3.1% | -54.7% | ||
| Q3 25 | 3.2% | -106.9% | ||
| Q2 25 | -8.0% | -64.8% | ||
| Q1 25 | 5.6% | -102.6% | ||
| Q4 24 | 1.0% | -74.3% | ||
| Q3 24 | 6.3% | -94.6% | ||
| Q2 24 | 3.6% | -79.1% | ||
| Q1 24 | -0.2% | -151.9% |
| Q4 25 | -5.4% | -62.0% | ||
| Q3 25 | -5.0% | -112.8% | ||
| Q2 25 | -12.8% | -69.0% | ||
| Q1 25 | 5.1% | -108.5% | ||
| Q4 24 | 331.5% | -80.9% | ||
| Q3 24 | 3.1% | -95.7% | ||
| Q2 24 | -0.4% | -89.5% | ||
| Q1 24 | 1.8% | -156.8% |
| Q4 25 | $-0.04 | $-1.28 | ||
| Q3 25 | $-0.04 | $-1.81 | ||
| Q2 25 | $-0.09 | $-1.17 | ||
| Q1 25 | $0.03 | $-1.57 | ||
| Q4 24 | $1.65 | $-1.34 | ||
| Q3 24 | $0.02 | $-1.40 | ||
| Q2 24 | $0.00 | $-1.52 | ||
| Q1 24 | $0.01 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $91.2M | $421.0M |
| 总债务越低越好 | $822.6M | — |
| 股东权益账面价值 | $2.0B | $-80.0M |
| 总资产 | $3.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.41× | — |
8季度趋势，按日历期对齐
| Q4 25 | $91.2M | $421.0M | ||
| Q3 25 | $64.1M | $202.5M | ||
| Q2 25 | $71.9M | $176.3M | ||
| Q1 25 | $282.9M | $127.1M | ||
| Q4 24 | $255.5M | $174.0M | ||
| Q3 24 | $305.8M | $150.6M | ||
| Q2 24 | $257.9M | $480.7M | ||
| Q1 24 | $267.6M | $112.3M |
| Q4 25 | $822.6M | — | ||
| Q3 25 | $838.9M | — | ||
| Q2 25 | $878.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $43.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.0B | $-80.0M | ||
| Q3 25 | $2.0B | $9.2M | ||
| Q2 25 | $2.0B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.0B | $255.0M | ||
| Q3 24 | $403.2M | $346.8M | ||
| Q2 24 | $380.6M | $432.4M | ||
| Q1 24 | $406.2M | $140.3M |
| Q4 25 | $3.0B | $1.5B | ||
| Q3 25 | $3.0B | $1.2B | ||
| Q2 25 | $3.0B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $623.5M | $1.5B | ||
| Q2 24 | $585.1M | $1.6B | ||
| Q1 24 | $547.8M | $1.3B |
| Q4 25 | 0.41× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.45× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $55.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $52.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 24.0% | -48.6% |
| 资本支出强度资本支出/营收 | 1.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $164.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $55.3M | $-99.8M | ||
| Q3 25 | $49.0M | $-91.4M | ||
| Q2 25 | $47.1M | $-108.3M | ||
| Q1 25 | $24.5M | $-166.5M | ||
| Q4 24 | $-29.2M | $-79.3M | ||
| Q3 24 | $49.6M | $-67.0M | ||
| Q2 24 | $43.9M | $-77.0M | ||
| Q1 24 | $10.0M | $-190.7M |
| Q4 25 | $52.3M | $-100.8M | ||
| Q3 25 | $44.9M | $-92.7M | ||
| Q2 25 | $44.1M | $-110.7M | ||
| Q1 25 | $23.0M | $-167.8M | ||
| Q4 24 | $-30.0M | $-79.5M | ||
| Q3 24 | $48.1M | $-68.6M | ||
| Q2 24 | $42.4M | $-79.0M | ||
| Q1 24 | $8.6M | $-193.9M |
| Q4 25 | 24.0% | -48.6% | ||
| Q3 25 | 21.9% | -58.0% | ||
| Q2 25 | 24.2% | -66.5% | ||
| Q1 25 | 18.2% | -120.5% | ||
| Q4 24 | -23.7% | -48.3% | ||
| Q3 24 | 41.5% | -49.2% | ||
| Q2 24 | 39.7% | -53.7% | ||
| Q1 24 | 8.4% | -178.2% |
| Q4 25 | 1.4% | 0.5% | ||
| Q3 25 | 2.0% | 0.8% | ||
| Q2 25 | 1.6% | 1.5% | ||
| Q1 25 | 1.2% | 1.0% | ||
| Q4 24 | 0.6% | 0.1% | ||
| Q3 24 | 1.3% | 1.2% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 1.4% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.76× | — | ||
| Q4 24 | -0.07× | — | ||
| Q3 24 | 13.66× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CWAN
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
